Category Archives: Topics

Diamyd to Move Forward with Ph3 Trial in HLA-Present T1DM Subpopulation; Additional Results from DIAGNODE-2

Yesterday, Diamyd Medical hosted a webcast to present additional details and context from the DIAGNODE-2 trial evaluating the effectiveness of Diamyd (treatment) in preserving endogenous insulin production. Recall, topline results for DIAGNODE-2 were announced earlier this week. Of note, DIAGNODE-2 showed no significant effect in HLA DR3-DQ2-absent T1DM patients as HLA-present patients were the only ones to respond to the treatment. Below, FENIX provides an overview of the results, thoughts on the Ph3 program, and insight into Diamyd’s potential to move forward without a partner.

This content is for Read Less members only.
Register
Already a member? Log in here

Thoughts on Cellectis’s CAR-T Program; Potential UCARTCS1 Protocol Changes; Q2 2020 Earnings Call

On Wednesday, August 5, Cellectis held their Q2 2020 conference call (press release). As expected, the company discussed the recent FDA hold on the UCARTCS1 Ph1 MELANI-01 trial in r/r MM. Management also stated that interim data will be presented for either UCART22 or UCART123 in Q4 2020, and that the Paris and Raleigh manufacturing sites remain on track to open later in 2020 and in 2021, respectively. Below, Celltelligence provides key takeaways from the call, and thoughts on Cellectis’s CAR-T program, particularly around the anticipated next steps for UCARTCS1.

This content is for Read Less members only.
Register
Already a member? Log in here

Abbott to Launch the First “Glucose Sport Biosensor”

Abbott announced plans to launch the novel “Libre Sense Glucose Sport Biosensor” (view website), which is intended to provide glucose readings and actionable insights to athletes with and without diabetes. Libre Sense has already received CE Mark, and Abbott said the product will be launched “in the coming weeks” to eight European countries via Abbott’s non-exclusive partnership with Phil Southerland’s Supersapiens (view Supersapiens website). Below, FENIX provides a brief overview of the Libre Sense Glucose Sport Biosensor and implications to the overall glucose-sensing market.

This content is for Read Less members only.
Register
Already a member? Log in here

Dexcom Announces New CGM Registry and Global Business Service Site in Lithuania; Dario Appoints Former LifeScan Exec to Scientific Advisory Board

Yesterday, a series of diabetes-related news items were observed: Dexcom announced its first registry committed to tracking in-hospital real-time CGM use outcomes; Dexcom announced plans to build a global business service center in Lithuania; and DarioHealth appointed Eric Milledge as chairman of its Scientific Advisory Board. Below, FENIX provides highlights and insights on the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Japanese NDA Submitted for Imeglimin; Poxel H1 ’20 Earnings Update

Yesterday, Poxel hosted its H1 ’20 earnings call and provided updates to its Japanese and US Imeglimin development. Of note, Poxel has submitted the Japanese NDA for Imeglimin and its US partner, Metavant, is actively preparing to initiate a Ph3 program in the US. Below, FENIX provides an overview of the Poxel earnings call and thoughts on Imeglimin development, including its market potential.

This content is for Read Less members only.
Register
Already a member? Log in here

Apple Cites T1DM Omnipod Patient Story at Tuesday Event; Jardiance Post-MI Trial (EMPACT-MI) Receives FDA FTD; Adocia Topline Results from M1Pram Ph1b Trial Extension; Welldoc/UMD Employs AI to Identify Digital Health Habits; Oramed’s Positive Diabetes Market Survey Results; Diamyd Receives $13.9M Towards Companion Medical Shares

A series of diabetes-related news items have been observed: Apple featured a T1DM patient story during the Apple Watch portion of its event; BI/Lilly announced Jardiance has received Fast Track designation for its EMPACT-MI study; Adocia announced positive topline results from its Ph1b M1Pram extension study in PWT1D; Welldoc and the University of Maryland’s Center for Health Information and Decision System (CHIDS) announced findings from a user engagement analysis; Oramed announced results from a diabetes market survey; and Diamyd received $13.9M from its divestment in Companion Medical. Below, FENIX provides highlights and insights from the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Senseonics Hosts Investor Event with Special Guest Ascensia

Today, Senseonics hosted a virtual investor event that also included a guest spot by Ascensia President, Robert Schumm. The goal of the event was to provide further detail to help inform financial analyst valuation models for SENS following the August 2020 partnership with Ascensia. Below, FENIX provides a summary and context from the information-rich event. 

This content is for Read Less members only.
Register
Already a member? Log in here

Diamyd’s Ph2b DIAGNODE-2 Trial Topline Results; New MicroTech Medical BGM 510(k) Clearance; Voluntis Announces €2M in Funding

A series of diabetes-related news items have been observed: Diamyd announced topline results from its Ph2b DIAGNODE-2 trial, and hosted a brief webcast to discuss the results; MicroTech received 510(k) clearance for its first BGM; and Voluntis secured €2M in financing. Below, FENIX provides highlights and insights related to the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Thoughts on Newly Permanent Lilly Insulin+Baqsimi Copay Cards; New Novo+ACC ASCVD Registry; ProSciento Receives VC Investment

A series of diabetes-related news items have been observed: Lilly permanently committed to the Insulin Value Program $35 copay card besides other savings options for Humulin R U500 and Baqsimi; Novo Nordisk and ACC are launching a new ASCVD T2DM registry; and ProSciento closed a venture capital funding round. Below, FENIX provides an overview of the respective news items as well as thoughts on the economic benefit of the $35 insulin copay card compared to Semglee in addition to how the ACC partnership is beneficial to Novo.

This content is for Read Less members only.
Register
Already a member? Log in here